Skip to content
Screener

Beta Bionics BBNX Financing Cash Flow

Financing Cash Flow at other companies

Insulet logo
InsuletPODD
-$319.9M-215%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$2.15M+105%
Medtronic logo
MedtronicMDT
-$888M+33.9%
Embecta Corp. logo
Embecta Corp.EMBC
$112.4M+280%
AdaptHealth logo
AdaptHealthAHCO
$52.56M+194%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
-$326.25M-9.1%

Other financials

Income statement

See full
Revenue$32.0M+37.8%
Gross profit$18.9M+51.2%
Operating income-$25.6M-28.7%
Net income-$23.4M-38.7%
EPS (diluted)-$0.53-35.9%

Balance sheet

See full
Cash & equivalents$44.3M+26.4%
Total debt$6.5M-2.6%
Total equity$256.4M-15.0%
Total assets$292.4M-11.4%

Cash flow

See full
Operating cash flow-$14.6M-7.6%
CapEx$1.0M-41.6%
Free cash flow-$15.7M-1.9%

Valuation

See full
Market cap$715.34M+15.1%
Enterprise value$677.53M+14.2%
P/S-2.0×

Profitability

See full
Gross margin58.3%+4.4pp
Operating margin-69.8%-8.0pp
Net margin-61.3%-15.8pp
FCF margin-51.6%-13.4pp

Returns & leverage

See full
Return on equity-26.2%
Debt / equity0.0×
Current ratio8.9×-5.8×

Where this comes from

Reported directly by Beta Bionics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Beta Bionics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:20 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-323777
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs195,430
Proceeds from the issuance of common stock from private placement, net of issuance costs15,591
Proceeds from stock option exercises and employee stock purchase plan issuances2,424140
Net cash provided by financing activities2,424211,161
Net increase in cash, cash equivalents and restricted cash12,7424,643
Cash, cash equivalents and restricted cash at beginning of period31,67630,532
Cash, cash equivalents and restricted cash at end of period$44,418$35,175
Supplemental disclosure of non-cash investing and financing information:

Item 1. Financial Statements.

FAQ

What is Beta Bionics's financing cash flow?
Beta Bionics (BBNX) reported financing cash flow of $1.8M in Q2 2026.
How has Beta Bionics's financing cash flow changed year-over-year?
Beta Bionics's financing cash flow increased by 4188.1% year-over-year, from $42K to $1.8M.
What is the long-term trend for Beta Bionics's financing cash flow?
Over 2 years (2023 to 2025), Beta Bionics's financing cash flow has grown at a 45.8% compound annual growth rate (CAGR), from $101.03M to $214.87M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Beta Bionics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude